 The study evaluated the effectiveness of antihistamines and a prepetent in treating proitis, itch, in psoriatic patients undergoing systemic antisoriatic therapies. The results showed that a prepetent displayed greater improvements than rupatidine in itch, quality of life, and sleepiness. Doubling the rupatidine dosage only slightly improved itch but did not modify the quality of life or increased sleepiness. Therefore, a prepetent may be a valid alternative for psoriatic patients with ESS greater than 14 under antihistamines. This article was authored by Giovanni Domiani, Calafcriding, Alessia Pacifico, and others.